ALS patients get extended access to experimental drug in safety Follow-Up
NCT ID NCT05299658
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 18 times
Summary
This study is for people with early-stage ALS who finished a previous trial of the experimental drug CNM-Au8. It aims to check the long-term safety of the treatment, not to cure the disease. About 40 participants will receive the drug openly, and researchers will monitor side effects and muscle function over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Concord Hospital
Concord, New South Wales, 2139, Australia
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
Conditions
Explore the condition pages connected to this study.